Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Felix Sogade

Clinical Cardiac Electrophysiology Macon, GA Medical Doctor

NPI 1992889505 CMS profile 317369

639 Hemlock St, Suite 100, Macon, GA 31201

Open in the dashboard

General payments

$109,306

523 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$765,706 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Felix Sogade of Macon, GA is reported in the CMS Open Payments database as having received $109,306 across 523 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $765,706 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 89th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,913 75
2024 General $27,382 86
2023 General $25,237 81
2022 General $15,113 66
2021 General $17,358 76
2020 General $11,648 38
2019 General $7,655 101

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Felix Sogade
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Felix Sogade were reported at $4,913. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Felix Sogade Clinical Cardiac Electrophysiology median Middle half National median
2019 $7,655 $2,361 $585–$8,260 $163
2020 $11,648 $993 $247–$4,351 $114
2021 $17,358 $1,185 $326–$4,739 $132
2022 $15,113 $2,073 $554–$6,789 $149
2023 $25,237 $2,568 $759–$8,159 $160
2024 $27,382 $2,557 $703–$7,403 $164
2025 $4,913 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Biosense Webster, Inc. $40,347 54 payments
  2. Medtronic, Inc. $35,243 104 payments
  3. Sanofi-Aventis U.S. LLC $15,202 13 payments
  4. Medtronic Vascular, Inc. $7,427 32 payments
  5. Boston Scientific Corporation $1,221 25 payments
  6. Abbott Laboratories $1,072 11 payments
  7. Medical Device Business Services, Inc. $1,012 2 payments
  8. Respicardia, Inc. $765 3 payments
  9. Pfizer Inc. $731 38 payments
  10. Alnylam Pharmaceuticals Inc. $690 14 payments
  11. Other $5,595 227 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $49,250 26 payments
  2. Travel and Lodging $25,449 75 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $19,095 5 payments
  4. Food and Beverage $15,418 412 payments
  5. Education $94 5 payments
Products named General payments · program years 2019–2025
  1. Carto 3 $27,882 25 payments
  2. Carto 3 System $6,545 10 payments
  3. CartoSound $6,425 9 payments
  4. Carto Smarttouch $6,425 9 payments
  5. Micra $1,552 6 payments
  6. EVERA MRI XT DR SURESCAN $1,462 8 payments
  7. Arctic Front Ablation $1,386 7 payments
  8. DIAMONDTEMP BIDIRECTIONAL ABLATION CATHETER $1,326 13 payments
  9. Arctic Front Ablation $1,050 8 payments
  10. AVEIR $1,042 9 payments
  11. Other $10,724 370 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 86 drugs

Part D claims

8,910

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$3,437,777

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

45.3%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 965 $917,093
Xarelto Rivaroxaban Brand 650 $581,972
Onpattro Patisiran Sodium,lipid Complex Brand 11 $439,147
Farxiga Dapagliflozin Propanediol Brand 302 $247,621
Entresto Sacubitril/Valsartan Brand 238 $241,579
Jardiance Empagliflozin Brand 259 $236,757
Camzyos Mavacamten Brand 12 $109,330
Mounjaro Tirzepatide Brand 84 $99,342
Ozempic Semaglutide Brand 86 $94,232
Multaq Dronedarone Hcl Brand 100 $89,477

The 10 drugs with the highest cost, of 86 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 80 billing codes

Paid by Medicare

$429,888

Medicare's payments for the services billed

Medicare patients

1,350

Average age 77

Services billed

9,553

679 women, 671 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 69%
Heart failure 61%
Ischemic heart disease 60%
Chronic kidney disease 52%
Arthritis 47%
Diabetes 46%
COPD 29%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AMVUTTRA
  • Alnylam Pharmaceuticals Inc. $327
$327 — —
VERQUVO
  • Merck Sharp & Dohme Corporation $85
$85 20 —
XARELTO
  • Janssen Pharmaceuticals, Inc $54
$54 650 —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $53
$53 259 —
WAINUA
  • AstraZeneca Pharmaceuticals LP $52
$52 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

523 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record